Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aimmune Therapeutics, Inc.    AIMT

AIMMUNE THERAPEUTICS, INC.

(AIMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Aimmune Therapeutics : shareholders accept $2 billion Nestle tender offer

10/13/2020 | 01:39am EST
Capsules of Palforzia are shown containing pharmaceutical grade peanut powder, for use in oral immunotherapy among patients with peanut allergies, manufactured by Aimmune Therapeutics

ZURICH (Reuters) - Aimmune Therapeutics Inc shareholders have backed Nestle's $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch due to the COVID-19 pandemic.

Including shares it already held, Nestle controlled around 84% of the outstanding shares as of the $34.50 per share offer's expiration date. "The minimum tender condition to the consummation of the offer set forth in the offer to purchase has been satisfied," Nestle said.

(Reporting by Michael Shields, editing by Kirsti Knolle)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
AIMMUNE THERAPEUTICS, INC. -0.29% 34.49 End-of-day quote.3.05%
NESTLÉ S.A. -2.14% 101.46 Delayed Quote.-1.05%
All news about AIMMUNE THERAPEUTICS, INC.
10/21Nestle shrugs off COVID-19 impact thanks to pet food and health nutrition
RE
10/19AIMMUNE THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Com..
AQ
10/19AIMMUNE THERAPEUTICS : Receives Positive CHMP Opinion on PALFORZIA for the Treat..
AQ
10/15MONTEVERDE & ASSOCIATES PC : Files Class Action Lawsuit On Behalf Of Shareholder..
PR
10/15AIMMUNE THERAPEUTICS : Nestle Completes Acquisition of Aimmune Therapeutics
AQ
10/13AIMMUNE THERAPEUTICS : Nestle announces results of tender offer for Aimmune Ther..
AQ
10/13GLOBAL MARKETS LIVE: U.S. banks beat expectations
10/13Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With S..
DJ
10/13AIMMUNE THERAPEUTICS : shareholders accept $2 billion Nestle tender offer
RE
09/18Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics..
PR
More news
Financials (USD)
Sales 2019 - - -
Net income 2019 -248 M - -
Net cash 2019 89,6 M - -
P/E ratio 2019 -8,43x
Yield 2019 -
Capitalization 2 268 M 2 268 M -
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees 339
Free-Float 77,8%
Chart AIMMUNE THERAPEUTICS, INC.
Duration : Period :
Aimmune Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 34,49 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Jayson Donald Alexander Dallas President, Chief Executive Officer & Director
Mark D. McDade Chairman
Eric Hands Claude Bjerkholt Chief Financial Officer
Daniel C. Adelman Chief Medical Officer
Narinder Singh Executive Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
AIMMUNE THERAPEUTICS, INC.3.05%2 268
GILEAD SCIENCES, INC.-7.49%75 350
VERTEX PHARMACEUTICALS-1.71%55 963
REGENERON PHARMACEUTICALS38.15%54 750
WUXI APPTEC CO., LTD.65.81%35 488
BEIGENE, LTD.71.43%25 903